New Vaccine Platforms (NVP) Program

The New Vaccine Platforms (NVP) Program aims to identify new vaccine platforms for the BARDA medical countermeasure (MCM) portfolio and advance them through a staged capability demonstration. The program seeks to identify technologies that are safe, effective across multiple infectious disease threats, and enable efficient development and manufacturing. The program is open to offerors that are either a single organization with a full technology solution or a two-part team that together offer a full technology solution. The program includes a staged capability demonstration across at least two emerging infectious disease threats, with stages including manufacturing demonstration, nonclinical demonstration, and clinical demonstration. • The program seeks to advance vaccine platforms that are safe, broadly protective across multiple infectious disease threats, and enable streamlined development and manufacturing. • The program is open to offerors that are either a single organization with a full technology solution or a two-part team that together offer a full technology solution. • The program includes a staged capability demonstration across at least two emerging infectious disease threats. • The program's objective is to ensure the U.S. MCM portfolio is optimally positioned to respond efficiently and effectively to national health security incidents.